New study data on anti-IL-36 therapy

Treatment options for generalized pustular psoriasis have been severely limited. Therefore, there is a high demand for new therapeutic options. Spesolimab is considered a promising hope. In a phase II study, the IL-36 receptor inhibitor excelled with rapid onset and sustained efficacy.